Daytime Boosts Immunity, Scientists Find
Press Release – University of Auckland
Kiwi scientists have discovered how daylight can boost the immune systems ability to fight infections.
A breakthrough study, led by scientists at Waipapa Taumata Rau, University of Auckland, has uncovered how daylight can boost the immune system's ability to fight infections.
The team focused on the most abundant immune cells in our bodies, called 'neutrophils', which are a type of white blood cell. These cells move quickly to the site of an infection and kill invading bacteria.
The researchers used zebrafish, a small freshwater fish, as a model organism, because its genetic make-up is similar to ours and they can be bred to have transparent bodies, making it easy to observe biological processes in real time.
'In earlier studies, we had observed that immune responses peaked in the morning, during the fish's early active phase,' says lead researcher Associate Professor Christopher Hall, from the Department of Molecular Medicine and Pathology.
'We think this represents an evolutionary response such that during daylight hours the host is more active so more likely to encounter bacterial infections,' says Hall.
However, the scientists wanted to find out how the immune response was being synchronised with daylight.
With this new study, published in Science Immunology, and led by two doctoral researchers, neutrophils were found to possess a circadian clock that alerted them to daytime, and boosted their ability to kill bacteria.
Most of our cells have circadian clocks to tell them what time of day it is in the outside world, in order to regulate the body's activities. Light has the biggest influence on resetting these circadian clocks.
'Given that neutrophils are the first immune cells to be recruited to sites of inflammation, our discovery has very broad implications for therapeutic benefit in many inflammatory diseases,' Hall says.
'This finding paves the way for development of drugs that target the circadian clock in neutrophils to boost their ability to fight infections.'
The research was funded through the Royal Society of NZ's Marsden Fund.
Current research is now focussed on understanding the specific mechanisms by which light influences the neutrophil circadian clock.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NZ Herald
a day ago
- NZ Herald
Prime Minister Christopher Luxon meets with Chinese President Xi Jinping in Beijing
Kiwi PhD students heading to US for world-leading space scholarships Three Victoria University of Wellington students are off to the Jet Propulsion Laboratory in California this week where experts work on NASA missions. Video / NZ Herald
NZ Herald
2 days ago
- NZ Herald
Crane driver snoozes through Donald Trump visit
Kiwi PhD students heading to US for world-leading space scholarships Three Victoria University of Wellington students are off to the Jet Propulsion Laboratory in California this week where experts work on NASA missions. Video / NZ Herald
Scoop
2 days ago
- Scoop
Clues To Diagnosing Parkinson's And MSA Discovered
Press Release – University of Auckland Australasian brain scientists have made a breakthrough that could help to diagnose Parkinson's disease and multiple system atrophy (MSA). Researchers at the University of Auckland's Centre for Brain Research – Dr Victor Dieriks and Dr James Wiseman – and University of Sydney Professor Glenda Halliday have discovered distinctive markers in the brains of people with the two diseases, which are often mistaken for one another in the early stages. 'It's vital to be able to accurately distinguish between Parkinson's and MSA early on, because this directly impacts on treatment decisions and patients' well-being,' says Dieriks. Currently, diagnosis of Parkinson's and MSA is based on patients' symptoms. Misdiagnosis often occurs, because the two conditions have similar symptoms. 'When misdiagnosed, patients with MSA are often given the Parkinson's drug, levodopa, which not only fails to help, but can worsen symptoms in some cases,' says Dieriks. While both conditions affect movement, Parkinson's typically progresses slowly with tremors, muscle stiffness, and slowness of movement. In contrast, MSA advances rapidly and includes problems such as severe balance issues, and disturbances in blood pressure and heart rate. The team used an innovative technique to study donated brain tissue in the Neurological Foundation Human Brain Bank in Auckland and the Sydney Brain Bank. They focused on a protein involved in both diseases – -synuclein – and found distinctive patterns and levels in Parkinson's, compared with MSA. 'We discovered this protein clumps differently in the brains of people with Parkinson's and MSA and the levels in MSA are far higher,' says Dieriks. Their discovery could pave the way for a simple, non-invasive test, such as a nasal swab, blood test, or urine sample, to reliably tell the two conditions apart. Lead researcher Wiseman says it's a significant breakthrough to be able to definitively diagnose Parkinson's and MSA from brain tissue. 'What's really exciting is we're a step closer to being able to diagnose these disorders by using readily available body fluids. 'This means we could pick up Parkinson's and MSA early, potentially before people even start to experience symptoms,' says Wiseman. Parkinson's disease affects millions globally, while MSA is far rarer, impacting about five in every 100,000 people. But MSA's toll is devastating, says Dieriks. 'MSA can turn active, independent people into individuals needing full-time care within just a few years. 'Whereas people with Parkinson's may live for decades, those with MSA typically survive only three to ten years after symptoms begin,' says Dieriks. Globally, research on Parkinson's is progressing rapidly, he says. 'We're closer than ever to developing a diagnostic test for Parkinson's. And the sooner we can catch these diseases, the better chance we have of slowing or stopping their progression.'
